Bernstein upgrades Sartorius to “outperform” on margin recovery, pharma demand

Bernstein upgraded Sartorius AG to "outperform" with a new price target of €272, citing a renewed margin expansion trajectory and an upturn in pharmaceutical capital spending. The upgrade is underpinned by robust performance in the BioProcess Solutions (BPS) division, which recorded an 8.8% increase in half-year sales and a 31.7% Q2 EBITDA margin, alongside expectations for a 34% group EBITDA margin by 2028. Analysts highlight the company's attractive valuation, trading at a 31% discount to its five-year average P/E despite projected 21.5% earnings growth through 2029, signaling significant upside potential amid a broader sector recovery.

Analysis

A recent upgrade of Sartorius AG (SATG) to “outperform” by Bernstein, with a price target increase to €272, is predicated on a strengthening operational and financial outlook. The core driver is the BioProcess Solutions (BPS) division, which constitutes 80% of revenue and delivered an 8.8% increase in half-year sales. Critically, the BPS division's Q2 EBITDA margin expanded by 309 basis points year-over-year to 31.7%, surpassing consensus estimates and signaling robust profitability from an improved product mix and cost efficiencies. This performance underpins Bernstein's forecast for a return to a 34% group EBITDA margin by 2028. The investment thesis is further supported by a compelling valuation; the stock trades at a 31% discount to its five-year average forward P/E of 51.8x, which appears mispriced against a projected 21.5% earnings growth rate through 2029. The company's strategic shift toward consumables has fortified its business model, with recurring revenues now accounting for approximately 79% of the total, enhancing financial stability. While the Lab Products & Services (LPS) division is weaker, it shows signs of stabilization, and broader sector indicators, including commentary from peers, suggest a recovery in biomanufacturing is underway. Identified risks, such as tariffs, are considered manageable, with an expected full-year margin impact of only 30-40 basis points.

Key Decisions for Investors

• Given the stock's 31% valuation discount to its historical average P/E alongside strong projected earnings growth of 21.5%, investors could consider the current price an attractive entry point, catalyzed by the positive analyst revision.
• Monitor the BioProcess Solutions (BPS) division's EBITDA margin as a primary performance indicator; sustained levels above 31% and progress toward the 34% long-term target would validate the core investment thesis.
• While management has mitigation strategies, investors should track the impact of tariffs and foreign exchange, as these remain the most tangible short-term risks to the company's otherwise strong margin expansion trajectory.
• Pay close attention to signs of recovery in the weaker Lab Products & Services (LPS) division and broader biomanufacturing order trends, as these will be key to confirming the sector-wide upturn and supporting sustained growth.